Merus Croissance future
Future contrôle des critères 2/6
Merus devrait augmenter ses bénéfices et son chiffre d'affaires de 19.1% et de 54.8% par an respectivement. Le BPA devrait croître de de 24.2% par an. Le rendement des capitaux propres devrait être -70.8% dans 3 ans.
Informations clés
19.1%
Taux de croissance des bénéfices
24.2%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 28.4% |
| Taux de croissance des recettes | 54.8% |
| Rendement futur des capitaux propres | -70.8% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 Nov 2024 |
Mises à jour récentes de la croissance future
Recent updates
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 05We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely
Sep 20
Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Aug 14Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts
Jun 01Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 12Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 84 | -274 | -272 | -232 | 14 |
| 12/31/2025 | 54 | -271 | -257 | -215 | 16 |
| 12/31/2024 | 36 | -248 | -219 | -190 | 15 |
| 9/30/2024 | 36 | -245 | -157 | -156 | N/A |
| 6/30/2024 | 35 | -168 | -104 | -103 | N/A |
| 3/31/2024 | 38 | -150 | -150 | -150 | N/A |
| 12/31/2023 | 44 | -155 | -146 | -142 | N/A |
| 9/30/2023 | 46 | -177 | -142 | -136 | N/A |
| 6/30/2023 | 41 | -178 | -159 | -150 | N/A |
| 3/31/2023 | 43 | -152 | -151 | -140 | N/A |
| 12/31/2022 | 42 | -131 | -158 | -150 | N/A |
| 9/30/2022 | 46 | -64 | -157 | -151 | N/A |
| 6/30/2022 | 53 | -54 | -137 | -133 | N/A |
| 3/31/2022 | 52 | -76 | -126 | -125 | N/A |
| 12/31/2021 | 49 | -67 | -60 | -60 | N/A |
| 9/30/2021 | 43 | -80 | -53 | -52 | N/A |
| 6/30/2021 | 38 | -89 | -42 | -41 | N/A |
| 3/31/2021 | 32 | -79 | -37 | -35 | N/A |
| 12/31/2020 | 30 | -86 | -81 | -80 | N/A |
| 9/30/2020 | 29 | -83 | -76 | -75 | N/A |
| 6/30/2020 | 28 | -69 | -80 | -78 | N/A |
| 3/31/2020 | 29 | -65 | -77 | -75 | N/A |
| 12/31/2019 | 31 | -55 | -66 | -63 | N/A |
| 9/30/2019 | 37 | -32 | -61 | -56 | N/A |
| 6/30/2019 | 35 | -34 | -63 | -58 | N/A |
| 3/31/2019 | 36 | -26 | -50 | -45 | N/A |
| 12/31/2018 | 38 | -28 | -50 | -46 | N/A |
| 9/30/2018 | 34 | -41 | -48 | -46 | N/A |
| 6/30/2018 | 33 | -45 | N/A | -43 | N/A |
| 3/31/2018 | 34 | -66 | N/A | -54 | N/A |
| 12/31/2017 | 26 | -78 | N/A | -45 | N/A |
| 9/30/2017 | 18 | -100 | N/A | -44 | N/A |
| 6/30/2017 | 12 | -87 | N/A | -33 | N/A |
| 3/31/2017 | 6 | -66 | N/A | -27 | N/A |
| 12/31/2016 | 3 | -50 | N/A | -27 | N/A |
| 9/30/2016 | 4 | -25 | N/A | -27 | N/A |
| 6/30/2016 | 3 | -26 | N/A | -30 | N/A |
| 3/31/2016 | 3 | -27 | N/A | -29 | N/A |
| 12/31/2015 | 2 | -25 | N/A | -25 | N/A |
| 9/30/2015 | 2 | -25 | N/A | -23 | N/A |
| 6/30/2015 | 2 | -23 | N/A | -19 | N/A |
| 3/31/2015 | 1 | -20 | N/A | -17 | N/A |
| 12/31/2014 | 2 | -21 | N/A | -18 | N/A |
| 12/31/2013 | 1 | -14 | N/A | -10 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: MRUS devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: MRUS devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: MRUS devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MRUS ( 54.8% par an) devrait croître plus rapidement que le marché US ( 9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MRUS ( 54.8% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: MRUS devrait être non rentable dans 3 ans.